Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals reported unaudited first-quarter 2026 group revenue of US$230 million, up 11% sequentially and 24% year-on-year, with its Precision Medicine segment growing 16% quarter-on-quarter on strong Illuccix and Gozellix sales. The company reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, citing increased U.S. dose volumes and expanding international launches as drivers of continued growth.
The company advanced its therapeutics pipeline, including positive safety and feasibility results from Part 1 of its global Phase 3 ProstACT trial for prostate cancer therapy TLX591-Tx and the opening of pivotal trials for TLX250-Tx in advanced kidney cancer and TLX101-Tx in recurrent glioblastoma. Regulatory momentum continued with resubmission of a U.S. NDA and a European MAA for its brain cancer imaging agents, and acceptance of an NDA for TLX591-Px in China, underscoring Telix’s push to broaden access to its radiopharmaceutical portfolio across major markets.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company focused on precision oncology, developing and commercialising diagnostic imaging agents and targeted radiopharmaceutical therapies. Its key products include PSMA PET imaging agents Illuccix and Gozellix, with a growing global footprint that supports future therapeutic launches in prostate, brain and kidney cancers.
YTD Price Performance: 15.62%
Average Trading Volume: 3,129,864
Technical Sentiment Signal: Sell
Current Market Cap: A$4.39B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.